// App-Quantinova.ai

233 : Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT

Researchers

Presenter

  • Myriam Labopin

Principal Investigators

  • Norbert Claude Gorin

  • Denis Caillot

  • Thibaut Leguay

  • Nicolaas Schaap

  • Mauricette Michallet

  • Gerard Socie

  • Mohamad Mohty

Medical Centers

  • Dept. of Hematology - BMT, Hopital St. Louis, Paris, France

  • Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

  • Clinical Hematology, Dijon University Hospital, Dijon, France

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Hematology, Hospital Saint Antoine, Paris, France,

  • Hematology-Oncology, Hopital Saint-Antoine and UniversitA A Pierre et Marie Curie UPMC, Paris, France

  • Service -Hematologie et Therapie Cellulaire, AP-HP, UPMC Universite Paris 6, UMR-S 938, CEREST-TC EBMT, Hopital Saint Antoine, Paris, France

  • Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland,

  • CHU Bordeaux - Hopital Haut-leveque, Pessac, France,

Locations

  • France

  • Poland

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Acute Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Estrogen receptor alpha

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved